What's Happening?
IntraBio Inc., a biopharmaceutical company based in Austin, Texas, has submitted a variation application to the European Medicines Agency (EMA) to expand the Marketing Authorization Application for AQNEURSA® (levacetylleucine) to include treatment for Ataxia-Telangiectasia
(A-T). A-T is a rare, inherited neurodegenerative disorder affecting coordination, speech, and immune function, with no current approved therapies. The application marks the first regulatory submission to the EMA for an A-T treatment. In the U.S., AQNEURSA has been granted Priority Review by the FDA, with a decision expected by September 19, 2026.
Why It's Important?
The submission of AQNEURSA for A-T treatment is a significant step in addressing a critical unmet medical need. A-T affects a small population but has severe implications, including increased cancer risk and life-threatening infections. Approval of AQNEURSA could provide the first therapeutic option for managing A-T symptoms, potentially improving patient quality of life and reducing healthcare burdens. This development also highlights the importance of regulatory pathways in facilitating access to treatments for rare diseases, which often lack commercial incentives for drug development.
What's Next?
The EMA will review the variation application for AQNEURSA, with the process involving validation and scientific assessment. If approved, AQNEURSA would become the first therapy for A-T in the European Economic Area. In the U.S., the FDA's Priority Review decision is anticipated by September 2026. Successful approvals could lead to increased research and development in rare neurodegenerative disorders, encouraging further innovation and investment in this field.
